Hyftor European Union - Bulgarian - EMA (European Medicines Agency)

hyftor

plusultra pharma gmbh - Сиролимус - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.